Antimalarials in cutaneous lupus erythematosus: Mechanisms of therapeutic benefit

Lupus

Volumn 11, Issue 2, 2002, Pages 71-81

  Wozniacka, A ^a   Carter, A ^b   McCauliffe, D P ^c  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antimalarials; Chloroquine; Cutaneous; Hydroxychloroquine; LE

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE;

ANTIGEN PRESENTATION; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYSOSOME; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; RISK BENEFIT ANALYSIS; SKIN LUPUS ERYTHEMATOSUS;

ANTIMALARIALS; APOPTOSIS; BLOOD PLATELETS; GLUCOSE; HUMANS; LIPID PEROXIDATION; LUPUS ERYTHEMATOSUS, CUTANEOUS; LYSOSOMES; PROSTAGLANDINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036207633     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu147rr     Document Type: Review

References (151)

1. Antimalarial therapy: A panacea for mild lupus?
2. The efficacy of antimalarials in systemic lupus erythematosus
3. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
4. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus
5. Cutaneous lupus erythematosus patients that smoke are less responsive to antimalarial treatment
6. Quinoline antimalarials: Mechanisms of action and resistance
7. The history of antimalarials
8. Activity of a new antimalarial agent, chloroquine (SN 7618)
9. Preparation of 7-chloro-4-[4-(n-ethyl, N-2-hydroxyethylamino)-1-methylbutylamino]-quinoline and related compounds
10. Pharmacokinetics of antimalarials and proposals for dosage regimens
11. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus
12. Comperative metabolic studies of chloroquine and hydroxychloroquine
13. The use of quinacrine (Atabrine) in rheumatic diseases: A reexamination
14. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus
15. Chloroquine-quinacrine association in resistant cutaneous lupus
16. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients
17. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus
18. Hydroxychloroquine in polymorphic light eruption: A controlled trial with drug and visual sensivity monitoring
19. Solar urticaria
20. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement
21. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: A critical review
22. Treatment of cutaneous sarcoidosis with chloroquine
23. Low-dose oral chloroquine with porphyria cutanea tarda
24. Lymphocytic infiltration of the skin
25. Generalized granuloma annulare (apparently responding well to chloroquine therapy)
26. A case of generalized granuloma annulare responding to hydroxychloroquine
27. Cutaneous cryptococosis; presentation of a case and review of previously reported cases
28. Tegumental leishmaniasis in Venezuela; presentation of several cases cured by glutantime and by synthetic antimalarials
29. Epidermolysis bullosa hereditaria treated with antimalarials
30. Acrodermatitis chronica atrophicans; report of a case treated with chloroquine phosphate
31. Antimalarials in dermatology
32. The treatment of dermatomyositis with hydroxychloroquine
33. The adjuvant therapy of pemphigus
34. Hydroxychloroquine in the treatment of chronic erythema nodosum
35. Chronic ulcerative stomatitis
36. Annular elastolytic giant cell granuloma: Sparing of a burn scar and successful treatment with chloroquine
37. Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial
38. The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease
39. The lysosomotropic amines, chloroquine and hydroxychloroquine: A potentially novel therapy for graft-versus-host disease
40. Treatment of eosinophilic annular erythema with chloroquine
41. REM syndrome: An immediate therapeutic response to hydroxychloroquine sulfate
42. Cutaneous lupus erythematosus
43. Antimalarials
44. Chloroquine phosphate: A long-term follow up of drug concentration in skin suction blister fluid and plasma
45. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers
46. Pharmacologic actions of 4-aminoquinoline compounds
47. Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis
48. Chloroquine and hydroxychloroquine in rheumatological therapy
49. Chloroquine treatment in rheumatoid arthritis
50. Studies on the mechanism of drug-binding to melanin
51. Absorption of antimalarial drugs in human skin: Spectroscopic and chemical analysis in epidermis and cornium
52. Anti-Malarial drugs: Possible mechanisms of action in autoimmune disease prospects for drug development
53. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by imparing receptor recycling
54. Dissimilar effects of anti-inflammatory drugs on stability of lysosomes from peritoneal and circulating leukocytes and liver
55. Studies on lysosome stabilization by antirheumatic drugs
56. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages
57. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of ph by various agents
58. Studies on the activity of selected lysosomal exoglycosidases in patients with systemic lupus erythematosus
59. Effects of tamoxifen, toremifene and chloroquine on the lysosomal enzymes in cultured retinal pigment epithelial cells
60. The effects of lysosomotrophic amines on protein degradation, migration of nonhistone proteins to the nucleus, and cathepsin D in lymphocytes
61. Autoimmune disease: A problem of defective apoptosis
62. Cigarette smoking enhances the elimination of quinine
63. Mechanism of action of hydroxychloroquine as an antirheumatic drug
64. Mechanism of action of antimalarial drugs: Inhibition of antigen processing and presentation
65. Major histocompatibility complex class II-restricted presentation of secreted and endoplasmic reticulum resident antigens requires the invariant chains and is sensitive to lysosomotrophic agents
66. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease
67. Chloroquine affects biosynthesis of Ia molecules by inhibiting dissociation of invariant (gamma) chains from alpha-beta dimers in B cells
68. Ultraviolet light modulation of autoantigens, epidermal cytokines and adhesion molecules as contributing factors of the pathogenesis of cutaneous LE
69. In vivo effects of chloroquine treatment on spontaneous and interferon-induced natural killer activities in rheumatoid arthritis patients
70. Effects of antimalarial drugs on human natural killer cell activity
71. Mannose 6-, fructose 1-, and fructose 6-phosphates inhibit human natural cell-mediated cytotoxicity
72. Inhibition of SK cell activity in frogs by certain drugs and sugars
73. Action of lysosomotrophic amines on spontaneous and interferon enhanced NK and CTL cytolysis
74. Arachidonic acid metabolism in guinea pig skin: Effects of chloroquine
75. Influence of niridazole and chloroquine on arterial and myometrial prostacyclin synthesis
76. Oral keratinocytes immortalized with the early region of human papillo-mavirus type 16 show elevated expression of interleukin 6, which acts as an autocrine growth factor for the derived T103c cell line
77. Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1b and tumor necrosis factor in macrofages: Implications for their mode of action in rheumatoid arthritis
78. Oxidative stress mediates synthesis of cytosolic phospholipase A2 after UVB injury
79. Hydroxy radical formation by UV-irradiated epidermal cells
80. UVB irradiation induces lipid peroxidation and reduces antioxidant enzyme activities in human keratinocytes in vivo
81. Mechanism of lipid radical formation following exposure of epidermal homogenate to ultraviolet light
82. Effects of ultraviolet A and B irradiation on lipid peroxidation and activity of the antioxidant enzymes in keratinocytes in culture
83. Ebselen inhibition of apoptosis by reduction of peroxides
84. A study of the mechanisms of chloroquine retinopathy. I. Chloroquine effect on lipid peroxidation of the retina
85. Inhibition of lipid peroxidation in muscle homogenates by phospholipase A2 inhibitors
86. Effects of chloroquine on lysosomal enzymes, NADPH-induced lipid peroxidation, and antioxidant enzymes of rat retina
87. Lysosomotropic agents ameliorate macrophage dysfunction following the phagocytosis of IgG-coated erythrocytes: A role for lipid peroxidation
88. Chloroquine-induced inhibition of the production of TNF, but not IL-6, is affected by disruption of iron metabolism
89. Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro
90. Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prostaglandin release
91. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor, interleukin 6, and interferon production by peripheral blood mononuclear cells
92. Chloroquine self-treatment and clinical outcome of cerebral malaria in children
93. Chloroquine inhibits macrophage tumor necrosis factor-alpha mRNA transcription
94. Chloroquine inhibits proinflammatory cytokine release into human whole blood
95. Selective regulation of cytokine secretion by hydroxychloroquine: Inhibition of interleukin 1 alpha (IL-1) and IL-6 in human monocytes and T cells
96. Immunosuppressive potential of antimalarials
97. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis
98. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
99. Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide
100. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus
101. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients
102. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients
103. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and a distinct photoregulation of transcription
104. The pathogenesis of rheumatoid arthritis: From molecules to the whole patient
105. Regulation of apoptosis in the immune system
106. Inhibition of programmed cell death by cyclosporine
107. Apoptosis induced in jurkat cells by several agents is preceded by intracellular acidification
108. Mechanisms of action of antimalarials in inflammation: Induction of apoptosis in human endothelial cells
109. Apoptosis induced by inhibitors of the plasma membrane NADH-oxidase involves Bcl-2 and calcineurin
110. Apoptosis related to chloroquine sensitivity of human malaria parasite Plasmodium falciparum
111. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine
112. Induction of apoptosis in primary culture of rat hepatocytes by protease inhibitors
113. Apoptosis in SLE: Too little or too much?
114. Action of chloroquine phosphate in rheumatoid arthritis. I. Immunosuppressive effect
115. Effect of chloroquine on erythematous and carcinogenic response to ultraviolet light
116. The efficiency of local application of chloroquine and mepacrine in preventing the effects of ultraviolet rays on human skin
117. Involvement of cytokines, DNA damage, and reactive oxygen intermediates in ultraviolet radiation-induced modulation of intercellular adhesion molecule-1 expression
118. Pathomechanisms of photosensitive lupus erythematosus
119. In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients
120. Photosensitivity caused by chloroquine
121. Sensitivity to UV light during treatment with chloroquine in rheumatoid arthritis
122. Topical chloroquine applied before irradiation protects against ultraviolet B (UVB)- and UVA-induced erythema but not against immediate pigment darkening
123. Effect of drugs on the early and late phase UV erythema
124. Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. The mechanism of action of hydroxychloroquine
125. Intradermal administration of chloroquine for discoid lupus erythematosus and lichen sclerosis et atrophicus
126. Effect of antimalarial treatment on circulating immune complexes in rheumatoid arthritis
127. Antioxidant action of antimalarials
128. On the inhibitory effect of chloroquine on blood platelet aggregation
129. Inhibition of very-low-density lipoprotein secretion by chloroquine, verapamil, and monensin takes place in the Golgi complex
130. Inhibition of hepatic cholesterol biosynthesis by chloroquine
131. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides: I. Effects of anti-inflammatory and disease-modifying drug treatment
132. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids
133. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus
134. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis
135. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs
136. Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus
137. In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance
138. The effects of low temperature and chloroquine on 1251-insulin degradation by the perfused rat liver
139. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug
140. Hydroxychloroquine use in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis
141. Hypoglycemia: An unusual adverse reaction to chloroquine
142. Chloroquine and hypoglycemia
143. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis
144. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotrophic mechanism
145. Serologic and HLA associations in subacute cutaneous lupus erythematosus
146. Subacute cutaneous lupus erythematosus: Genetic markers and clinical and immunological findings in patients
147. Subacute cutaneous lupus erythematosus-immunogenetic associations
148. A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans
149. Prevention of post-operative deep venous thrombosis and pulmonary embolism
150. Prevention of postoperative deep venous thrombosis in leg by orally administered hydroxychloroquine sulfate
151. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?